PFE ▲ +2.1% - Pfizer Inc.
$PFE Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer
07-OCT-2026 12:57 PM ET
Share this post
More filings for $PFE
PFE ▲ +2.3% - Pfizer Inc.Oct 7, 2026PFE ▲ +0.3% - Pfizer Inc.Oct 6, 2026PFE ▲ +0.3% - Pfizer Inc.Oct 6, 2026PFE ▼ -1.2% - Pfizer Inc.Oct 2, 2026PFE ▼ -1.2% - Pfizer Inc.Oct 2, 2026PFE ▼ -0.5% - Pfizer Inc.Oct 1, 2026
View full $PFE filing history →💬 Comments
Loading comments…
Leave a comment